ARWR News and Press, Arrowhead Pharmaceuticals Inc.

– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...

2024-06-05 11:50:05 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: Hoping Something Sticks Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript Ar...

2024-06-05 05:00:08 ET Andrea Tan from Goldman Sachs issued a price target of $31.00 for ARWR on 2024-06-05 02:24:00. The adjusted price target was set to $31.00. At the time of the announcement, ARWR was trading at $25.29. The overall price target consensus is at $60.00...

2024-06-03 12:24:00 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: Hoping Something Sticks Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point Arrowhead Pharmaceuticals secures $50M milestone from Royalty Pharma Arrow...

- Plozasiran achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10 - Plozasiran achieved a statistically significant reduction in incidence of acute pancreatitis versus placebo - Plozasiran is the company’...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 16 th European Glaucoma Society (EGS) Congress – June 1-4, 2024 Title: Development and Characterization of Trabecular Meshwork Targeted RNA...

- Zodasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins across all dose levels at Week 24 - Data presented at European Atherosclerosis Society 92 nd Congress and simultaneously published in the New England Journal of Medicine Arrowhead Pharma...

- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol - Data presented at European Atherosclerosis Society 92 nd Congress and simultaneously published in the New England Journal of Medicine Arrowhead Pharma...

2024-05-27 10:05:29 ET Summary Arrowhead Pharmaceuticals' stock has dropped more than 70% from its June 2021 high, causing concerns about its near-term outlook. The company's lead therapy, plozasiran, is currently behind Ionis Pharmaceuticals' olezarsen for two hypertriglyceridemi...